Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)

Trial Profile

Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Bremelanotide (Primary)
  • Indications Female sexual dysfunction
  • Focus Registrational; Therapeutic Use
  • Acronyms RECONNECT
  • Sponsors Palatin Technologies
  • Most Recent Events

    • 27 Feb 2017 Results published in an AMAG Pharmaceuticals media release.
    • 27 Feb 2017 According to an AMAG Pharmaceuticals media release, additional results from the study were presented at the International Society for the Study of Women's Sexual Health (ISSWSH) Annual Meeting.
    • 14 Feb 2017 According to an AMAG Pharmaceuticals media release, Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top